Modulation of Transthyretin Expression
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 8,697,860 | Diagnosis and Treatment of Disease In force · Medium confidence UsedRemaining | Ionis Pharmaceuticals, Inc. | In force | Medium confidence | ||
| US 9,061,044 | Modulation of Transthyretin Expression In force · Low confidence | Ionis Pharmaceuticals, Inc. | In force | Low confidence | ||
| US 9,399,774 | Modulation of Transthyretin Expression In force · Medium confidence | Ionis Pharmaceuticals, Inc. | In force | Medium confidence | ||
| US 9,816,092 | Modulation of Transthyretin Expression In force · Low confidence | Ionis Pharmaceuticals, Inc. | In force | Low confidence | ||
| Application 13/098,303 | Modulation of Transthyretin Expression Abandoned Abandoned Nov 5, 2013 | Isis Pharmaceuticals, Inc. | Abandoned | Abandoned Nov 5, 2013 | ||
| Application 15/729,860 | Modulation of Transthyretin Expression Abandoned Abandoned Jan 15, 2019 | Ionis Pharmaceuticals, Inc. | Abandoned | Abandoned Jan 15, 2019 |
6 of 6 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
1 of these is in force and held by Isis Pharmaceuticals, Inc..
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.